]
October 14, 2021

WHO Global Tuberculosis Report—New Drugs and Regimens Need to be Combined with Equitable and Universal Access

Statement by Mel Spigelman, MD, President and Chief Executive Officer, TB Alliance
September 30, 2021

TB Alliance Welcomes New Board Members

Dr. Eric Goosby, Sundar Kodiyalam, David Y. Norton, and Sangita Reddy Join Board
August 19, 2021

TB Alliance Convenes Community Engagement Stakeholders to Discuss Clinical Trial Updates

During a virtual forum on August 12, 2021 speakers shared experiences and updates on engaging with communities for research and development programs
July 15, 2021

Launch of UNITE4TB partnership marks a new era in Tuberculosis treatment development

The partnership will accelerate the development of new Tuberculosis (TB) drug regimens as part of the Innovative Medicines Initiative (IMI), a public-private European Research & Development Consortium
June 29, 2021

TB Alliance Congratulates Dr. Dan Everitt on Career Transition

As Chief Medical Officer, Dr. Everitt played key role in advancing TB therapy
April 15, 2021

A Persistent Shortfall in TB Research and Development Funding

Statement on 2020 G-FINDER Report

Pages